Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][13]. Core Insights - The controlling shareholder, Juzi Holding, plans to increase its stake in the company by at least HKD 200 million within 3-6 months, reflecting strong confidence in the company's future [2][3]. - The company aims to enhance its brand, expand distribution channels, and strengthen regulatory approvals, focusing on product development and marketing efforts [4]. - The projected earnings per share (EPS) for 2025-2027 are estimated at CNY 2.40, CNY 2.93, and CNY 3.54, with corresponding price-to-earnings (PE) ratios of 23, 19, and 16 [5][11]. Summary by Sections Event Commentary - Juzi Holding announced a plan to increase its shareholding, indicating confidence in the company's prospects [2]. Operational Analysis - Juzi Holding currently holds approximately 54.26% of the company's shares and plans to acquire an additional 3.268 million shares, representing about 0.3% of the total share capital [3]. - The company will focus on increasing R&D investment and enhancing its product offerings, particularly in three categories of medical devices [4]. Future Outlook - The company plans to strengthen its marketing for key brands and develop new brands to support growth in its skincare business [4]. - The product matrix, including medical devices and skincare lines, is expected to continue driving growth [5]. Financial Forecasts - Revenue is projected to grow from CNY 3,524 million in 2023 to CNY 10,921 million by 2027, with a compound annual growth rate (CAGR) of approximately 23.95% [11]. - Net profit is expected to increase from CNY 1,452 million in 2023 to CNY 3,790 million by 2027, reflecting a strong growth trajectory [11].
巨子生物：增持彰显信心，把握超跌机会-20250610